Sol-Gel Technologies Ltd (SLGL)

Nov 15, 2024, 7:00 AM EST - 4 months ago

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Aug 17, 2024, 11:27 AM EDT - 8 months ago

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 16, 2024, 7:00 AM EDT - 8 months ago

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jul 15, 2024, 7:00 AM EDT - 9 months ago

Sol-Gel Technologies Announces Management Realignment

May 20, 2024, 7:00 AM EDT - 11 months ago

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 16, 2024, 6:00 AM EDT - 11 months ago

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Nov 30, 2023, 7:00 AM EST - 1 year ago

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Nov 28, 2023, 8:06 AM EST - 1 year ago

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Nov 9, 2023, 7:00 AM EST - 1 year ago

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 6, 2023, 7:30 AM EDT - 1 year ago

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

May 12, 2023, 7:00 AM EDT - 2 years ago

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Mar 20, 2023, 7:00 AM EDT - 2 years ago

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Mar 10, 2023, 7:00 AM EST - 2 years ago

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Jan 27, 2023, 7:29 AM EST - 2 years ago

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Jan 27, 2023, 7:00 AM EST - 2 years ago

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Nov 10, 2022, 4:00 AM EST - 2 years ago

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 3, 2022, 8:00 AM EDT - 2 years ago

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Aug 4, 2022, 6:00 AM EDT - 2 years ago

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

May 13, 2022, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Apr 25, 2022, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Apr 14, 2022, 8:30 AM EDT - 3 years ago

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Mar 30, 2022, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Mar 25, 2022, 11:00 AM EDT - 3 years ago

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Dec 22, 2021, 4:05 PM EST - 3 years ago

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Dec 21, 2021, 7:00 AM EST - 3 years ago

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Nov 11, 2021, 7:00 AM EST - 3 years ago

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Nov 9, 2021, 7:05 AM EST - 3 years ago

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Sep 22, 2021, 7:30 AM EDT - 3 years ago

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sep 9, 2021, 8:30 AM EDT - 3 years ago

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Aug 4, 2021, 7:05 AM EDT - 3 years ago

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Jul 27, 2021, 10:26 AM EDT - 4 years ago

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

Jul 27, 2021, 9:15 AM EDT - 4 years ago

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Jul 20, 2021, 7:05 AM EDT - 4 years ago

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Jun 28, 2021, 5:10 AM EDT - 4 years ago

Sol-Gel Announces Pipeline Update and Future Development Plans

Jun 28, 2021, 5:00 AM EDT - 4 years ago

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

May 13, 2021, 7:05 AM EDT - 4 years ago

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

Apr 27, 2021, 12:03 PM EDT - 4 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX CYCN

Apr 27, 2021, 10:02 AM EDT - 4 years ago

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

Mar 4, 2021, 7:05 AM EST - 4 years ago

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update

Feb 24, 2021, 7:05 AM EST - 4 years ago

Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference

Jan 11, 2021, 7:05 AM EST - 4 years ago

Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference

Dec 7, 2020, 7:05 AM EST - 4 years ago

Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris

Nov 19, 2020, 9:00 AM EST - 4 years ago

Sol-Gel: Slow And Steady Topical Technology

Nov 12, 2020, 8:21 AM EST - 4 years ago

Recap: Sol-Gel Technologies Q3 Earnings

Nov 12, 2020, 7:05 AM EST - 4 years ago

Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update